Neutrophil-to-lymphocyte ratio in combination with PD-L1 or lactate dehydrogenase as biomarkers for high PD-L1 non-small cell lung cancer treated with first-line pembrolizumab

The identification of prognostic and predictive biomarkers for high-programmed cell death-ligand 1 (PD-L1) advanced non-small cell lung cancer (aNSCLC) treated with first-line pembrolizumab could support the decision-making about possible combination therapies. To explore the baseline neutrophil-to-...

Descripción completa

Detalles Bibliográficos
Autores principales: Banna, Giuseppe Luigi, Signorelli, Diego, Metro, Giulio, Galetta, Domenico, De Toma, Alessandro, Cantale, Ornella, Banini, Marco, Friedlaender, Alex, Pizzutillo, Pamela, Garassino, Marina Chiara, Addeo, Alfredo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7481583/
https://www.ncbi.nlm.nih.gov/pubmed/32953525
http://dx.doi.org/10.21037/tlcr-19-583

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7481583/
https://www.ncbi.nlm.nih.gov/pubmed/32953525
http://dx.doi.org/10.21037/tlcr-19-583

Ejemplares similares